Tofacitinib

Routes
Oral (PO)
Half-Life (t½)
PO: 3h
Formula
C16H20N6O
Molecular Weight
312.37 g/mol
PubChem CID
9926791
Aliases
Xeljanz

Pharmacological Mechanism

JAK1/JAK3 inhibitor — same class effect as baricitinib. Approved for RA, psoriatic arthritis, ulcerative colitis. ORAL Surveillance trial showed worse CV + malignancy signal vs TNFi → boxed warning.

Half-Life & Elimination Curve (PO: 3h)

100%50%25%12.5%0%0h0×t½3h1×t½6h2×t½9h3×t½12h4×t½15h5×t½0×t½ (0h): 100% remaining (~57.6 µg/L)1×t½ (3h): 50% remaining (~28.8 µg/L)2×t½ (6h): 25% remaining (~14.4 µg/L)3×t½ (9h): 12.5% remaining (~7.2 µg/L)4×t½ (12h): 6.3% remaining (~3.6 µg/L)5×t½ (15h): 3.1% remaining (~1.8 µg/L)
Plasma (PO)t½ Decay (3h)Effect Site (ke0)
  • 0×t½0h100% (57.6 µg/L)
  • 1×t½3h50% (28.8 µg/L)
  • 2×t½6h25% (14.4 µg/L)
  • 3×t½9h12.5% (7.2 µg/L)
  • 4×t½12h6.3% (3.6 µg/L)
  • 5×t½15h3.1% (1.8 µg/L)
Elimination t½3h (PO)
Rate Constant (ke)0.231 h⁻¹
Time to Peak (Tmax)1.54h
Est. Peak (Cmax)57.6 µg/L
Clearance (CL)20.8 L/h
97% Washout (5×t½)15h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References